Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 49 - Preparations for testing in vivo
Patents for A61K 49 - Preparations for testing in vivo (35,376)
05/2010
05/14/2010WO2010053218A1 Fluorinated benzothiazole derivatives, preparation method thereof and imaging agent for diagnosing altzheimer's disease using the same
05/14/2010WO2010053101A1 Eye drop having high intraocular migration properties, fluorescent imaging agent, and methods for producing same
05/14/2010WO2010052503A1 Detection of cancer
05/14/2010WO2010052394A1 Ivabradine used as a diagnosis agent in a method for coronary angiography using multiple-cut tomodensitometry
05/14/2010WO2010008876A3 Method for preparation of micellar hybrid nanoparticles for therapeutic and diagnostic applications and compositions thereof
05/14/2010WO2010008519A3 In vitro diagnostic markers comprising carbon nanoparticles and kits
05/14/2010WO2009154425A3 Multimodal imaging method using nano-emulsion comprising optical nano-particles and perfluorocarbons
05/14/2010CA2742831A1 Fusogenic properties of saposin c and related proteins and peptides for application to transmembrane drug delivery systems
05/14/2010CA2742515A1 Modulators of cxcr7
05/13/2010US20100122357 Human albumin animal models for drug evaluation, toxicology and immunogenicity studies
05/13/2010US20100122356 Pig model for psoriasis
05/13/2010US20100122355 Transgenic Reporter Mouse and Method for Use
05/13/2010US20100120688 ErbB Interface Peptidomimetics And Methods Of Use Thereof
05/13/2010US20100119459 Use of ivabradine as diagonstic agent in the method of coronary angiography by multislice computed tomography
05/13/2010US20100119458 Compositions Containing Metal Oxide Particles and Their Use
05/13/2010US20100119457 Composition of labeled and non-labeled monoclonal antibodies
05/13/2010US20100119456 Administering a therapeutic agent with more than one taggant
05/13/2010US20100119455 Administering a therapeutic agent with more than one taggant
05/13/2010US20100119454 Use of the conserved Drosophila NPFR1 system for uncovering interacting genes and pathways important in nociception and stress response
05/13/2010US20100119453 Methods of enhancing functioning of the large intestine
05/13/2010US20100119452 Screening method
05/13/2010US20100119451 Methods of using in situ hydration of hydrogel articles for sealing or augmentation of tissue or vessels
05/13/2010US20100119450 Soluble low-density lipoprotein receptor related protein binds directly to alzheimer's amyloid-beta peptide
05/13/2010US20100119449 Sox11 expression in malignant lymphomas
05/12/2010EP2184607A1 Immune response assessment method
05/12/2010EP2184262A1 Process for production of surface-coated inorganic particles
05/12/2010EP2184065A1 Use of ivabradine as a diagnostic agent in the coronary angiography method using multi-cut computed tomography
05/12/2010EP2182835A1 Device and procedure for the diagnosis or diagnostic preparation and/or therapy monitoring of inflammatory diseases such as rheumatoid arthritis
05/12/2010CN201453412U Animal intravenous infusion administration device
05/12/2010CN1985996B Microbulb ultrasonic contrast medium and its connection method with antibody, targeting gene and gene
05/12/2010CN1973832B Biodegradable nanometer medicine capsule with CT trace effect and its preparation process
05/12/2010CN1879892B Method for establishing extranodal nasal type NK/T-celllymphoma animal model
05/12/2010CN1860990B Biological simulation system and recording medium
05/12/2010CN101707869A Polyglutamate conjugates and polyglutamate-amino acid conjugates having a plurality of drugs
05/12/2010CN101703785A Amphipathic super-paramagnetic and magnetically resonant contrast agent and preparation method thereof
05/12/2010CN101703784A Magnetic resonance tumor targeted contrast agent and preparation method thereof
05/11/2010US7713962 Introducing into the subject a ligand capable of labelling aggregated paired helical filament (PHF) tau protein, determining the presence and/or amount of ligand bound to extracellular aggregated PHF tau in the medial temporal lobe of the brain, correlating the result of the determination
05/11/2010US7713517 Compositions and methods for enhancing contrast in imaging
05/11/2010US7713516 use of a ligand contained in the selected contrast agent as a pharmaceutical active agent for treating the patient, as a carrier for a pharmaceutical active agent, as a ligand of a further contrast agent and/or as an "in vitro" diagnostic reagent
05/11/2010US7713515 Methods and compositions for use in diagnosing and characterizing diseases involving abnormal apoptosis
05/11/2010US7713514 Multilayer binding; lamellar surface structure containing at least two binding compounds is assembled under conditions in which the binding compounds self-regulate in or on the lamellar structure; organized mobile multifunctional conjugate (OMMC) assembly
05/11/2010CA2223261C Improved delivery of diagnostic and therapeutic agents to a target site
05/06/2010WO2010051544A2 Rapid homogeneous diagnostic testing platform based on lanthanide fluorescent resonance energy transfer
05/06/2010WO2010050528A1 Anti-muc1 antibody
05/06/2010WO2010048768A1 Nitroimidazole-amino acid compound type nuclide hypoxia imaging agent and intermediates for preparing them
05/06/2010WO2010048708A1 System and method for magnetic resonance imaging
05/06/2010US20100115638 Method for inhibiting the expression of endogenous erythropoietin (epo)
05/06/2010US20100113861 Metallic nanoparticles with coated shells and applications of same
05/06/2010US20100113755 Isolated modified human chorionic gonadotropin proteins
05/06/2010US20100112685 Thymidine Kinase Mutants and Fusion Proteins Having Thymidine Kinase and Guanylate Kinase Activities
05/06/2010US20100111974 Treatment of Cachexia
05/06/2010US20100111875 Trisubstituted triazamacrocyclic compounds and their use as contrast agents
05/06/2010US20100111874 Method of cancer detection and treatment
05/06/2010US20100111873 Treating cancer with viral nucleic acid
05/06/2010US20100111872 System and method for modulating and optimizing immunotherapy
05/06/2010US20100111871 Photoacoustic probes and methods of imaging
05/06/2010US20100111870 Evaluation method and screening method for substance having action of activating/suppressing innate immunity, agent and food product for activating/suppressing innate immune mechanism and method for producing the same
05/06/2010US20100111869 Stinging cells expressing an exogenous polynucleotide encoding a therapeutic, diagnostic or a cosmetic agent and methods compositions and devices utilizing such stinging cells or capsules derived therefrom for delivering the therapeutic, diagnostic or cosmetic agent into a tissue
05/06/2010US20100111868 Monoclonal antibodies for neutralizing anthrax toxin
05/06/2010US20100111867 Carborane-phosphonium compounds and their use in boron neutron capture therapy and imaging
05/06/2010US20100111866 Receptor and Antigen Targeted Prodrug
05/06/2010US20100111865 Contrast agents
05/06/2010US20100111859 Visualization of Biological Material by the Use of Coated Contrast Agents
05/06/2010US20100111850 Compositions and methods for administering compartmentalized frozen particles
05/06/2010US20100111849 Compositions and methods for administering compartmentalized frozen particles
05/06/2010US20100111848 Compositions and methods for administering compartmentalized frozen particles
05/06/2010US20100111847 Compositions and methods for administering compartmentalized frozen particles
05/06/2010US20100111845 Compositions and methods for therapeutic delivery with frozen particles
05/06/2010US20100111844 Compositions and methods for therapeutic delivery with frozen particles
05/06/2010US20100111843 Compositions and methods for therapeutic delivery with frozen particles
05/06/2010US20100111842 Compositions and methods for therapeutic delivery with frozen particles
05/06/2010US20100111837 Compositions and methods for biological remodeling with frozen particle compositions
05/06/2010US20100111835 Compositions and methods for therapeutic delivery with frozen particles
05/06/2010US20100111833 Compositions and methods for surface abrasion with frozen particles
05/06/2010US20100111832 Compositions and methods for surface abrasion with frozen particles
05/06/2010CA2741798A1 Anti-muc1 antibody
05/06/2010CA2741668A1 Novel substituted azabenzoxazoles
05/05/2010EP2182078A1 Biomarkers and methods for determining sensitivity to vascular endothelial growth factor receptor-2 modulators
05/05/2010EP2181706A2 Florfenicol esters for treating bacterial infections
05/05/2010EP2180902A2 Imaging medium comprising hyperpolarised ¹³c-acetate and use thereof
05/05/2010EP2180881A2 Vesicles comprising a transmembrane transport trigger system
05/05/2010EP1715897B1 High frequency ultrasound imaging using contrast agents
05/05/2010CN1953757B Composition for cleaning intestinal canal
05/05/2010CN1909779B Method for sifting nerve active compound and related nerve plasticity
05/05/2010CN1630817B Method for sample identification in a mammal as well as a kit for performing this method
05/05/2010CN101701011A Pyrazine derivatives, methods of use, and methods for preparing same
05/05/2010CN101700418A Developed degradable polymer composites and preparation method thereof
05/05/2010CN101700402A Intestinal wall discriminative gadolinium-contained nano-contrast agent particle and preparation method thereof
05/05/2010CN101700401A Polyalkylene glycol with moiety for conjugating biologicallyactive compound
05/04/2010US7709207 Method for identifying compounds for treatment of pain
05/04/2010US7708979 Thermogelling polymer blends for biomaterial applications
05/04/2010US7708977 Method for diagnosis and treatment of vascular disease
05/04/2010CA2335364C Use of bi-specific antibodies for pre-targeting diagnosis and therapy
04/2010
04/30/2010CA2665773A1 Neurotoxic sterol glycosides
04/29/2010WO2010048623A2 Medical and imaging nanoclusters
04/29/2010WO2010048311A1 Animal model for evaluating vasomotor response in vivo
04/29/2010WO2010048268A2 Manganese-oxo clusters as contrast agents for magnetic resonance imaging
04/29/2010WO2010047829A1 Mutant hepatitis c virus e2 polypeptides for hcv treatment
04/29/2010WO2010046796A1 Molecular imaging
04/29/2010WO2010011856A3 Stereospecificity of methylsulfinyl reduction
1 ... 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 ... 354